Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
Trial record 1 of 1 for:    ea5152
Previous Study | Return to List | Next Study

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03468985
Recruitment Status : Active, not recruiting
First Posted : March 19, 2018
Last Update Posted : January 22, 2020
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This partially randomized phase II trial studies how well nivolumab, cabozantinib s-malate, and ipilimumab work in treating patients with stage IV non-small cell lung cancer that has come back. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab, cabozantinib s-malate, and ipilimumab may work better than cabozantinib s-malate alone in treating patients with stage IV non-small cell lung cancer.

Condition or disease Intervention/treatment Phase
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma Recurrent Lung Non-Squamous Non-Small Cell Carcinoma Stage IV Lung Non-Small Cell Cancer AJCC v7 Drug: Cabozantinib Drug: Cabozantinib S-malate Biological: Ipilimumab Other: Laboratory Biomarker Analysis Biological: Nivolumab Other: Questionnaire Administration Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 169 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC
Actual Study Start Date : March 1, 2018
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm A (nivolumab)
Patients receive nivolumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Other: Laboratory Biomarker Analysis
Correlative studies

Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo

Other: Questionnaire Administration
Ancillary studies

Experimental: Arm B (nivolumab, cabozantinib s-malate)
Patients receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Cabozantinib
Given PO

Drug: Cabozantinib S-malate
Given PO
Other Names:
  • BMS-907351
  • Cabometyx
  • Cometriq
  • XL-184
  • XL184

Other: Laboratory Biomarker Analysis
Correlative studies

Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo

Other: Questionnaire Administration
Ancillary studies

Experimental: Arm C (nivolumab, cabozantinib s-malate, ipilimumab)
Patients receive nivolumab IV over 60 minutes on day 1, cabozantinib s-malate PO daily on days 1-28, and ipilimumab IV over 90 minutes every 8 weeks. Cycles for nivolumab and cabozantinib s-malate repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Cabozantinib
Given PO

Drug: Cabozantinib S-malate
Given PO
Other Names:
  • BMS-907351
  • Cabometyx
  • Cometriq
  • XL-184
  • XL184

Biological: Ipilimumab
Given IV
Other Names:
  • Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
  • BMS-734016
  • MDX-010
  • MDX-CTLA4
  • Yervoy

Other: Laboratory Biomarker Analysis
Correlative studies

Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo

Other: Questionnaire Administration
Ancillary studies

Experimental: Arm T (nivolumab, cabozantinib s-malate, ipilimumab)
Patients with ROS1 gene rearrangement, MET exon 14 splice mutations, MET high amplification, or RET gene rearrangement receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Cabozantinib
Given PO

Drug: Cabozantinib S-malate
Given PO
Other Names:
  • BMS-907351
  • Cabometyx
  • Cometriq
  • XL-184
  • XL184

Other: Laboratory Biomarker Analysis
Correlative studies

Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo

Other: Questionnaire Administration
Ancillary studies




Primary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: From randomization to documented disease progression or death from any cause, whichever occurs first, assessed up to 5 years ]
    Will be estimated using the Kaplan-Meier method and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparison of PFS will use a logrank test stratified on the randomization stratification factors with a one-sided type I error rate of 10%. Other comparisons of groups will be made using the logrank test and Cox modeling.


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: From randomization to death from any cause, assessed up to 5 years ]
    Will be estimated using the Kaplan-Meier method and Cox proportional hazards models will be used to estimate the treatment hazard ratios.

  2. Best objective response evaluated [ Time Frame: Up to 5 years ]
    According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Response rates (complete response and partial response) will be compared using Fischer's exact tests with a one-sided type I error rate of 10%; multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes.

  3. Incidence of toxicity [ Time Frame: Up to 5 years ]
    Evaluated according to Common Terminology Criteria for Adverse Events version 5 criteria. Toxicity will be compared using Fischer's exact tests with a one-sided type I error rate of 10%; multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes.


Other Outcome Measures:
  1. Time to tumor response [ Time Frame: Up to 5 years ]
    As measured by RECIST 1.1 criteria.

  2. Comparison of RECIST 1.1 imaging response assessment measurements [ Time Frame: Up to 5 years ]
  3. Effects of tobacco on provider-reported cancer-treatment toxicity (adverse events (both clinical and hematologic) and dose modifications [ Time Frame: Up to 5 years ]
    A combined analysis of the data from the selected Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN) trials is planned. Data collected from the tobacco use assessment in each parent study will not be analyzed and reported in the clinical study report.

  4. Effects of tobacco on patient-reported physical symptoms and psychological symptoms [ Time Frame: Up to 5 years ]
    A combined analysis of the data from the selected ECOG-ACRIN trials is planned. Data collected from the tobacco use assessment in each parent study will not be analyzed and reported in the clinical study report.

  5. Assessment of quitting behaviors, behavioral counseling/support and cessation medication utilization [ Time Frame: Up to 5 years ]
    A combined analysis of the data from the selected ECOG-ACRIN trials is planned. Data collected from the tobacco use assessment in each parent study will not be analyzed and reported in the clinical study report.

  6. Effects of tobacco use and exposure on treatment duration, relative dose intensity, and therapeutic benefit [ Time Frame: Up to 5 years ]
    A combined analysis of the data from the selected ECOG-ACRIN trials is planned. Data collected from the tobacco use assessment in each parent study will not be analyzed and reported in the clinical study report.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ELIGIBILITY CRITERIA FOR STEP 0
  • Patients with tumors with the following molecular alterations must submit testing results via Medidata Rave to determine eligibility to Arm T; the study chair, co-chair, biology co-chair, or a delegate must review the molecular testing and agree that the testing meets one of the molecular eligibility criteria below:

    • ROS1 gene rearrangement by fluorescence in situ hybridization (FISH) or deoxyribonucleic acid (DNA) analysis (may have progressed on prior crizotinib therapy)
    • MET exon 14 splice mutations on DNA analysis (may have progressed on prior crizotinib therapy)
    • MET high amplification by FISH or DNA analysis or other MET mutations predicted to be sensitive to MET inhibitor (no prior targeted therapy allowed)
    • RET gene rearrangement by FISH or DNA analysis (no prior targeted therapy allowed)

      • Institutions will be notified of the patient's eligibility status for Arm T within two (2) business days of submission of the molecular testing reports
      • If patients do not have tumors with the above molecular alterations noted proceed directly to step 1
  • ELIGIBILITY CRITERIA FOR STEP 1
  • For patients with known molecular alterations, institution has been notified that patient is deemed eligible for Arm T per review of molecular testing reports
  • Pathologically confirmed non-squamous non-small cell lung carcinoma (NSCLC)
  • Stage IV disease (includes M1a, M1b, or recurrent disease), according to the 7th edition of the lung cancer tumor, node, and metastasis (TNM) classification system
  • Predominant non-squamous histology (patients with NSCLC not otherwise specified [NOS] are eligible); mixed tumors will be categorized by the predominant cell type; if small cell elements are present the patient is ineligible
  • Tumors must be tested and known negative for EGFR tyrosine kinase inhibitor (TKI) sensitizing mutations (EGFR exon 19 deletions, L858R, L861Q, G719X) and ALK gene rearrangements by routine Clinical Laboratory Improvement Act (CLIA)-certified clinical testing methods; negative circulating tumor DNA results alone are not acceptable; prior testing for tumor PD-L1 status is not required
  • Patients must have progressed radiographically following first line platinum-based chemotherapy, no additional lines of therapy are permitted

    • NOTE: Prior adjuvant chemotherapy for early stage disease does not count as one line of therapy if 12 months or greater elapsed between completion of adjuvant therapy and initiation of first-line systemic therapy; if less than 12 months elapsed, adjuvant chemotherapy counts as one line of therapy
    • Exception for targeted therapy sub-study (Arm T): At least one line of prior chemotherapy or targeted therapy is required, but there is no limit on number of prior treatments
  • Patients must have measurable disease as defined by RECIST v. 1.1 criteria; baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to registration
  • No prior anti-MET therapy such as crizotinib or cabozantinib, or PD-1/PD-L1 immune checkpoint inhibitor therapy (such as nivolumab, pembrolizumab, atezolizumab) or CTLA4 inhibitor therapy (such as ipilimumab); no prior allergic reaction to small molecule tyrosine kinase inhibitors or monoclonal antibodies

    • Exception for targeted therapy sub-study (Arm T): Prior crizotinib may be allowed depending on the gene alteration
  • Any prior chemotherapy (based on administration schedule) must have been completed in greater than or equal to the following times prior to registration:

    • Chemotherapy/ targeted oral therapy administered in a daily or weekly schedule must be completed >= 1 week prior to registration;
    • Any chemotherapy administered in an every 2 week or greater schedule must be completed >= 2 weeks prior to registration
    • Additionally, patients should be recovered to equal to or less than grade 1 toxicities related to any prior treatment, unless adverse event (AE)(s) are clinically nonsignificant and/or stable on supportive therapy
  • No prior radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks prior to registration
  • Patients with no known brain metastasis must have baseline brain imaging within 12 weeks prior to study registration not demonstrating brain metastases OR
  • Patients with known brain metastases must have baseline brain imaging within 4 weeks prior to study registration and meet all of the following criteria:

    • Have completed treatment to all symptomatic brain metastases (with whole brain radiation or radiosurgery) >= 4 weeks prior to registration, or have undergone complete neurosurgical resection >= 3 months prior to registration
    • Be clinically stable from brain metastases at time of screening, if no treatment was administered
    • Known leptomeningeal disease is not allowed
  • Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-1

    • NOTE: Participants with impaired decision-making capacity (IDMC) should not be allowed to participate in this study due to its complexity
  • Patients must have anticipated life expectancy greater than 3 months
  • Absolute neutrophil count >= 1,500/mm^3 (within 2 weeks prior to registration)
  • Platelets >= 100,000/mm^3 (within 2 weeks prior to registration)
  • Hemoglobin >= 9 g/dL (within 2 weeks prior to registration)
  • Subject has prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) test =< 1.3 x the laboratory upper limit of normal (ULN) (within 2 weeks prior to registration)
  • Total bilirubin =< 1.5 x ULN (within 2 weeks prior to registration)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x ULN (within 2 weeks prior to registration)
  • Serum albumin >= 2.8 g/dL (within 2 weeks prior to registration)
  • Serum calcium (absolute or albumin corrected), magnesium and potassium >= lower limit of normal (LLN) (within 2 weeks prior to registration)

    • NOTE: serum calcium, magnesium and potassium can be replaced if values are below LLN
  • Creatinine =< 1.5 x ULN or calculated (Cockcroft-Gault formula) or measured creatinine clearance >= 50 mL/min/1.73 m^2 (normalized to body surface area [BSA]) for patients with creatinine levels greater than 1.5 times the institutional normal (within 2 weeks prior to registration)
  • Screening urine dipstick must equal 0 or "trace"; if urine dipstick results are >= 1+, or if dipstick was not performed, calculation of urine protein creatinine (UPC) is required and patients must have a UPC ratio =< 1 to participate in the study (within 2 weeks prior to registration)
  • No history of the following:

    • Clinically-significant gastrointestinal bleeding within 6 months prior to registration
    • Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months prior to registration
    • Drug induced pneumonitis within 3 months prior to registration
    • Signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
    • Radiographic evidence of cavitating pulmonary lesion(s)
    • Tumor invading any major blood vessels
    • Evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or mainstem endobronchial tumor within 28 days before the first dose of cabozantinib
  • No concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel); allowed anticoagulants are the following:

    • Low-dose aspirin for cardioprotection (per local applicable guidelines) is permitted
    • Low molecular weight heparins (LMWH) or unfractionated heparin is permitted
    • Anticoagulation with therapeutic doses of LMWH is allowed in subjects without known brain metastases who are on a stable dose of LMWH for at least 6 weeks before first dose of study treatment, and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
  • No concomitant treatment of strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's wort)
  • No cardiovascular disorders including:

    • Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening
    • Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic, or > 100 mm Hg diastolic despite optimal antihypertensive treatment within 7 days prior to registration
    • Any of the following within 6 months prior to registration:

      • Unstable angina pectoris
      • Clinically-significant cardiac arrhythmias
      • Stroke (including transient ischemic attack [TIA], or other ischemic event)
      • Myocardial infarction
  • No gastrointestinal disorders associated with a high risk of perforation or fistula formation within 3 months prior to registration:

    • Active peptic ulcer disease
    • Inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis
    • Known malabsorption syndrome
    • Bowel obstruction or gastric outlet obstruction
    • Percutaneous endoscopic gastrostomy (PEG) tube placement
  • No gastrointestinal disorders associated with a high risk of perforation or fistula formation within 6 months prior to registration:

    • Abdominal fistula
    • Gastrointestinal perforation
    • Intra-abdominal abscess; Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 6 months prior to registration
  • None of the following conditions:

    • Grade 3 or greater infection, or infection requiring intravenous systemic treatment within 28 days prior to registration; patients should be off antibiotics at the time of registration.
    • Serious non-healing wound/ulcer/bone fracture within 28 days prior to registration
    • History of organ transplant
    • Concurrent symptomatic untreated hypothyroidism within 7 days prior to registration
    • History of surgery as follows:

      • Major surgery (as an example, surgery requiring anesthesia and a > 24 hour hospital stay) within 3 months prior to registration, with wound healing at least 28 days prior to registration
      • Minor surgery within 28 days prior to registration with complete wound healing at least 10 days prior to registration
      • Minor procedures within 7 days prior to registration such as thoracentesis, paracentesis, or 18 g or smaller needle biopsy of tumor
      • Patients with clinically relevant ongoing complications from prior surgery are not eligible
  • Patients must have corrected QT interval calculated by the Fridericia formula (QTcF) =< 500 ms within 28 days before registration
  • Patients must be able to swallow tablets
  • No currently active other malignancies which require systemic treatment
  • No patients that have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
  • No patients with known active autoimmune disease or known history of autoimmune disease for which recurrence may affect vital organ function or require immune suppressive treatment including systemic corticosteroids; these include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, autoimmune hepatitis; patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease; patients with vitiligo, endocrine deficiencies including type I diabetes mellitus or thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible; patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
  • No ongoing major illness or psychosocial issues that would limit compliance with the protocol
  • Women must not be pregnant or breast-feeding due to contraindications with the study agents

    • All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
    • A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must use an accepted and effective method of contraception or abstain from sexual intercourse for at least one week prior to the start of treatment, and continue for 5 months after the last dose of protocol treatment for women of childbearing potential and 7 months after the last dose of protocol treatment for males who are sexually active with WOCBP
  • Patients with known human immunodeficiency virus (HIV) disease taking antiretroviral therapy are excluded because there are no safety data with the combination of antiretroviral therapy and cabozantinib or ipilimumab or nivolumab with ipilimumab

    • Patients with known chronic active hepatitis B (defined as a positive hepatitis B surface antigen and/or hepatitis B viral load in the last

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03468985


Locations
Hide Hide 468 study locations
Layout table for location information
United States, Alaska
Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States, 98508
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States, 99508
Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States, 99508
Alaska Women's Cancer Care
Anchorage, Alaska, United States, 99508
Anchorage Oncology Centre
Anchorage, Alaska, United States, 99508
Katmai Oncology Group
Anchorage, Alaska, United States, 99508
Providence Alaska Medical Center
Anchorage, Alaska, United States, 99508
United States, Arkansas
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas, United States, 71913
Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas, United States, 72401
United States, California
PCR Oncology
Arroyo Grande, California, United States, 93420
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, United States, 91505
United States, Colorado
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, United States, 80907
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado, United States, 80907
Porter Adventist Hospital
Denver, Colorado, United States, 80210
Mercy Medical Center
Durango, Colorado, United States, 81301
Southwest Oncology PC
Durango, Colorado, United States, 81301
Mountain Blue Cancer Care Center
Golden, Colorado, United States, 80401
Rocky Mountain Cancer Centers-Lakewood
Lakewood, Colorado, United States, 80228
Saint Anthony Hospital
Lakewood, Colorado, United States, 80228
Littleton Adventist Hospital
Littleton, Colorado, United States, 80122
Longmont United Hospital
Longmont, Colorado, United States, 80501
Rocky Mountain Cancer Centers-Longmont
Longmont, Colorado, United States, 80501
Parker Adventist Hospital
Parker, Colorado, United States, 80138
Rocky Mountain Cancer Centers-Parker
Parker, Colorado, United States, 80138
Saint Mary Corwin Medical Center
Pueblo, Colorado, United States, 81004
Rocky Mountain Cancer Centers - Pueblo
Pueblo, Colorado, United States, 81008
Rocky Mountain Cancer Centers-Thornton
Thornton, Colorado, United States, 80260
United States, Florida
Broward Health Medical Center
Fort Lauderdale, Florida, United States, 33316
United States, Georgia
University Cancer and Blood Center LLC
Athens, Georgia, United States, 30607
Dekalb Medical Center
Decatur, Georgia, United States, 30033
United States, Idaho
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States, 83706
Saint Luke's Mountain States Tumor Institute
Boise, Idaho, United States, 83712
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, United States, 83605
Kootenai Medical Center
Coeur d'Alene, Idaho, United States, 83814
Walter Knox Memorial Hospital
Emmett, Idaho, United States, 83617
Saint Luke's Mountain States Tumor Institute - Fruitland
Fruitland, Idaho, United States, 83619
Idaho Urologic Institute-Meridian
Meridian, Idaho, United States, 83642
Saint Luke's Mountain States Tumor Institute - Meridian
Meridian, Idaho, United States, 83642
Saint Alphonsus Medical Center-Nampa
Nampa, Idaho, United States, 83686
Saint Luke's Mountain States Tumor Institute - Nampa
Nampa, Idaho, United States, 83686
Kootenai Cancer Center
Post Falls, Idaho, United States, 83854
Kootenai Cancer Clinic
Sandpoint, Idaho, United States, 83864
Saint Luke's Mountain States Tumor Institute-Twin Falls
Twin Falls, Idaho, United States, 83301
United States, Illinois
Rush - Copley Medical Center
Aurora, Illinois, United States, 60504
Illinois CancerCare-Bloomington
Bloomington, Illinois, United States, 61704
Illinois CancerCare-Canton
Canton, Illinois, United States, 61520
Memorial Hospital of Carbondale
Carbondale, Illinois, United States, 62902
SIH Cancer Institute
Carterville, Illinois, United States, 62918
Illinois CancerCare-Carthage
Carthage, Illinois, United States, 62321
Centralia Oncology Clinic
Centralia, Illinois, United States, 62801
Carle on Vermilion
Danville, Illinois, United States, 61832
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, United States, 62526
Decatur Memorial Hospital
Decatur, Illinois, United States, 62526
Carle Physician Group-Effingham
Effingham, Illinois, United States, 62401
Crossroads Cancer Center
Effingham, Illinois, United States, 62401
Illinois CancerCare-Eureka
Eureka, Illinois, United States, 61530
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, United States, 60201
Illinois CancerCare-Galesburg
Galesburg, Illinois, United States, 61401
Western Illinois Cancer Treatment Center
Galesburg, Illinois, United States, 61401
NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois, United States, 60026
NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois, United States, 60035
Edward Hines Jr VA Hospital
Hines, Illinois, United States, 60141
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, United States, 61443
Illinois CancerCare-Macomb
Macomb, Illinois, United States, 61455
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, United States, 61938
Trinity Medical Center
Moline, Illinois, United States, 61265
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, United States, 61350
Illinois CancerCare-Pekin
Pekin, Illinois, United States, 61554
Illinois CancerCare-Peoria
Peoria, Illinois, United States, 61615
Methodist Medical Center of Illinois
Peoria, Illinois, United States, 61636
Illinois CancerCare-Peru
Peru, Illinois, United States, 61354
Valley Radiation Oncology
Peru, Illinois, United States, 61354
Illinois CancerCare-Princeton
Princeton, Illinois, United States, 61356
SwedishAmerican Regional Cancer Center/ACT
Rockford, Illinois, United States, 61114
North Shore Medical Center
Skokie, Illinois, United States, 60076
Southern Illinois University School of Medicine
Springfield, Illinois, United States, 62702
Springfield Clinic
Springfield, Illinois, United States, 62702
Memorial Medical Center
Springfield, Illinois, United States, 62781
Cancer Care Specialists of Illinois-Swansea
Swansea, Illinois, United States, 62226
Southwest Illinois Health Services LLP
Swansea, Illinois, United States, 62226
Carle Cancer Center
Urbana, Illinois, United States, 61801
The Carle Foundation Hospital
Urbana, Illinois, United States, 61801
Rush-Copley Healthcare Center
Yorkville, Illinois, United States, 60560
United States, Indiana
Parkview Hospital Randallia
Fort Wayne, Indiana, United States, 46805
Parkview Regional Medical Center
Fort Wayne, Indiana, United States, 46845
Reid Health
Richmond, Indiana, United States, 47374
United States, Iowa
Mary Greeley Medical Center
Ames, Iowa, United States, 50010
McFarland Clinic PC - Ames
Ames, Iowa, United States, 50010
McFarland Clinic PC-Boone
Boone, Iowa, United States, 50036
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, United States, 50325
Mercy Cancer Center-West Lakes
Clive, Iowa, United States, 50325
Alegent Health Mercy Hospital
Council Bluffs, Iowa, United States, 51503
Greater Regional Medical Center
Creston, Iowa, United States, 50801
Iowa Methodist Medical Center
Des Moines, Iowa, United States, 50309
Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa, United States, 50309
Broadlawns Medical Center
Des Moines, Iowa, United States, 50314
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, United States, 50314
Mercy Medical Center - Des Moines
Des Moines, Iowa, United States, 50314
Iowa Lutheran Hospital
Des Moines, Iowa, United States, 50316
McFarland Clinic PC-Trinity Cancer Center
Fort Dodge, Iowa, United States, 50501
Trinity Regional Medical Center
Fort Dodge, Iowa, United States, 50501
McFarland Clinic PC-Jefferson
Jefferson, Iowa, United States, 50129
McFarland Clinic PC-Marshalltown
Marshalltown, Iowa, United States, 50158
Methodist West Hospital
West Des Moines, Iowa, United States, 50266-7700
Mercy Medical Center-West Lakes
West Des Moines, Iowa, United States, 50266
United States, Kansas
Central Care Cancer Center - Garden City
Garden City, Kansas, United States, 67846
Central Care Cancer Center - Great Bend
Great Bend, Kansas, United States, 67530
Lawrence Memorial Hospital
Lawrence, Kansas, United States, 66044
Kansas Institute of Medicine Cancer and Blood Center
Lenexa, Kansas, United States, 66219
Minimally Invasive Surgery Hospital
Lenexa, Kansas, United States, 66219
Menorah Medical Center
Overland Park, Kansas, United States, 66209
Cancer Center of Kansas-Wichita Medical Arts Tower
Wichita, Kansas, United States, 67208
Cancer Center of Kansas - Wichita
Wichita, Kansas, United States, 67214
United States, Kentucky
Flaget Memorial Hospital
Bardstown, Kentucky, United States, 40004
Baptist Health Corbin
Corbin, Kentucky, United States, 40701
Commonwealth Cancer Center-Corbin
Corbin, Kentucky, United States, 40701
Baptist Health Lexington
Lexington, Kentucky, United States, 40503
Saint Joseph Radiation Oncology Resource Center
Lexington, Kentucky, United States, 40504
Saint Joseph Hospital East
Lexington, Kentucky, United States, 40509
Saint Joseph London
London, Kentucky, United States, 40741
Jewish Hospital
Louisville, Kentucky, United States, 40202
Baptist Health Louisville
Louisville, Kentucky, United States, 40207
Saints Mary and Elizabeth Hospital
Louisville, Kentucky, United States, 40215
Jewish Hospital Medical Center Northeast
Louisville, Kentucky, United States, 40245
Baptist Health Madisonville/Merle Mahr Cancer Center
Madisonville, Kentucky, United States, 42431
Baptist Health Paducah
Paducah, Kentucky, United States, 42003
Jewish Hospital Medical Center South
Shepherdsville, Kentucky, United States, 40165
United States, Louisiana
Ochsner Health Center-Summa
Baton Rouge, Louisiana, United States, 70809
Medical Center of Baton Rouge
Baton Rouge, Louisiana, United States, 70816
Ochsner Medical Center Jefferson
New Orleans, Louisiana, United States, 70121
United States, Maryland
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, United States, 21201
Greater Baltimore Medical Center
Baltimore, Maryland, United States, 21204
Western Maryland Regional Medical Center
Cumberland, Maryland, United States, 21502
Peninsula Regional Medical Center
Salisbury, Maryland, United States, 21801
United States, Michigan
Hickman Cancer Center
Adrian, Michigan, United States, 49221
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, United States, 48106
IHA Hematology Oncology Consultants-Brighton
Brighton, Michigan, United States, 48114
Saint Joseph Mercy Brighton
Brighton, Michigan, United States, 48114
IHA Hematology Oncology Consultants-Canton
Canton, Michigan, United States, 48188
Saint Joseph Mercy Canton
Canton, Michigan, United States, 48188
Caro Cancer Center
Caro, Michigan, United States, 48723
IHA Hematology Oncology Consultants-Chelsea
Chelsea, Michigan, United States, 48118
Saint Joseph Mercy Chelsea
Chelsea, Michigan, United States, 48118
Hematology Oncology Consultants-Clarkston
Clarkston, Michigan, United States, 48346
Newland Medical Associates-Clarkston
Clarkston, Michigan, United States, 48346
Ascension Saint John Hospital
Detroit, Michigan, United States, 48236
Great Lakes Cancer Management Specialists-Doctors Park
East China Township, Michigan, United States, 48054
Genesee Cancer and Blood Disease Treatment Center
Flint, Michigan, United States, 48503
Genesee Hematology Oncology PC
Flint, Michigan, United States, 48503
Genesys Hurley Cancer Institute
Flint, Michigan, United States, 48503
Hurley Medical Center
Flint, Michigan, United States, 48503
Academic Hematology Oncology Specialists
Grosse Pointe Woods, Michigan, United States, 48236
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Grosse Pointe Woods, Michigan, United States, 48236
Michigan Breast Specialists-Grosse Pointe Woods
Grosse Pointe Woods, Michigan, United States, 48236
Sparrow Hospital
Lansing, Michigan, United States, 48912
Hope Cancer Clinic
Livonia, Michigan, United States, 48154
Saint Mary Mercy Hospital
Livonia, Michigan, United States, 48154
Great Lakes Cancer Management Specialists-Macomb Medical Campus
Macomb, Michigan, United States, 48044
Michigan Breast Specialists-Macomb Township
Macomb, Michigan, United States, 48044
Saint Mary's Oncology/Hematology Associates of Marlette
Marlette, Michigan, United States, 48453
Toledo Clinic Cancer Centers-Monroe
Monroe, Michigan, United States, 48162
21st Century Oncology-Pontiac
Pontiac, Michigan, United States, 48341
Hope Cancer Center
Pontiac, Michigan, United States, 48341
Newland Medical Associates-Pontiac
Pontiac, Michigan, United States, 48341
Saint Joseph Mercy Oakland
Pontiac, Michigan, United States, 48341
Huron Medical Center PC
Port Huron, Michigan, United States, 48060
Lake Huron Medical Center
Port Huron, Michigan, United States, 48060
Great Lakes Cancer Management Specialists-Rochester Hills
Rochester Hills, Michigan, United States, 48309
Ascension Saint Mary's Hospital
Saginaw, Michigan, United States, 48601
Oncology Hematology Associates of Saginaw Valley PC
Saginaw, Michigan, United States, 48604
Bhadresh Nayak MD PC-Sterling Heights
Sterling Heights, Michigan, United States, 48312
Ascension Saint Joseph Hospital
Tawas City, Michigan, United States, 48764
Advanced Breast Care Center PLLC
Warren, Michigan, United States, 48088
Great Lakes Cancer Management Specialists-Macomb Professional Building
Warren, Michigan, United States, 48093
Macomb Hematology Oncology PC
Warren, Michigan, United States, 48093
Michigan Breast Specialists-Warren
Warren, Michigan, United States, 48093
Saint John Macomb-Oakland Hospital
Warren, Michigan, United States, 48093
Saint Mary's Oncology/Hematology Associates of West Branch
West Branch, Michigan, United States, 48661
Huron Gastroenterology PC
Ypsilanti, Michigan, United States, 48106
IHA Hematology Oncology Consultants-Ann Arbor
Ypsilanti, Michigan, United States, 48197
United States, Minnesota
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, United States, 56601
Fairview Ridges Hospital
Burnsville, Minnesota, United States, 55337
Mercy Hospital
Coon Rapids, Minnesota, United States, 55433
Fairview-Southdale Hospital
Edina, Minnesota, United States, 55435
Unity Hospital
Fridley, Minnesota, United States, 55432
Fairview Maple Grove Medical Center
Maple Grove, Minnesota, United States, 55369
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, United States, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, United States, 55109
Abbott-Northwestern Hospital
Minneapolis, Minnesota, United States, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, United States, 55415
Health Partners Inc
Minneapolis, Minnesota, United States, 55454
New Ulm Medical Center
New Ulm, Minnesota, United States, 56073
North Memorial Medical Health Center
Robbinsdale, Minnesota, United States, 55422
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, United States, 55416
Regions Hospital
Saint Paul, Minnesota, United States, 55101
United Hospital
Saint Paul, Minnesota, United States, 55102
Saint Francis Regional Medical Center
Shakopee, Minnesota, United States, 55379
Lakeview Hospital
Stillwater, Minnesota, United States, 55082
Sanford Thief River Falls Medical Center
Thief River Falls, Minnesota, United States, 56701
Ridgeview Medical Center
Waconia, Minnesota, United States, 55387
Rice Memorial Hospital
Willmar, Minnesota, United States, 56201
Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota, United States, 55125
Sanford Cancer Center Worthington
Worthington, Minnesota, United States, 56187
Fairview Lakes Medical Center
Wyoming, Minnesota, United States, 55092
United States, Mississippi
Singing River Hospital
Pascagoula, Mississippi, United States, 39581
United States, Missouri
Central Care Cancer Center - Bolivar
Bolivar, Missouri, United States, 65613
Parkland Health Center-Bonne Terre
Bonne Terre, Missouri, United States, 63628
Saint Francis Medical Center
Cape Girardeau, Missouri, United States, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, United States, 63703
Centerpoint Medical Center LLC
Independence, Missouri, United States, 64057
Capital Region Southwest Campus
Jefferson City, Missouri, United States, 65109
Research Medical Center
Kansas City, Missouri, United States, 64132
Missouri Baptist Medical Center
Saint Louis, Missouri, United States, 63131
Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri, United States, 63670
Missouri Baptist Sullivan Hospital
Sullivan, Missouri, United States, 63080
Missouri Baptist Outpatient Center-Sunset Hills
Sunset Hills, Missouri, United States, 63127
United States, Montana
Community Hospital of Anaconda
Anaconda, Montana, United States, 59711
Billings Clinic Cancer Center
Billings, Montana, United States, 59101
Bozeman Deaconess Hospital
Bozeman, Montana, United States, 59715
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, United States, 59405
Great Falls Clinic
Great Falls, Montana, United States, 59405
Saint Peter's Community Hospital
Helena, Montana, United States, 59601
Kalispell Regional Medical Center
Kalispell, Montana, United States, 59901
Saint Patrick Hospital - Community Hospital
Missoula, Montana, United States, 59802
Community Medical Hospital
Missoula, Montana, United States, 59804
United States, Nebraska
CHI Health Saint Francis
Grand Island, Nebraska, United States, 68803
Heartland Hematology and Oncology
Kearney, Nebraska, United States, 68845
CHI Health Good Samaritan
Kearney, Nebraska, United States, 68847
Saint Elizabeth Regional Medical Center
Lincoln, Nebraska, United States, 68510
Nebraska Methodist Hospital
Omaha, Nebraska, United States, 68114
Alegent Health Immanuel Medical Center
Omaha, Nebraska, United States, 68122
Hematology and Oncology Consultants PC
Omaha, Nebraska, United States, 68122
Alegent Health Bergan Mercy Medical Center
Omaha, Nebraska, United States, 68124
Alegent Health Lakeside Hospital
Omaha, Nebraska, United States, 68130
Creighton University Medical Center
Omaha, Nebraska, United States, 68131
Midlands Community Hospital
Papillion, Nebraska, United States, 68046
United States, Nevada
Carson Tahoe Regional Medical Center
Carson City, Nevada, United States, 89703
Cancer and Blood Specialists-Henderson
Henderson, Nevada, United States, 89052
Comprehensive Cancer Centers of Nevada - Henderson
Henderson, Nevada, United States, 89052
Comprehensive Cancer Centers of Nevada-Horizon Ridge
Henderson, Nevada, United States, 89052
Las Vegas Cancer Center-Henderson
Henderson, Nevada, United States, 89052
OptumCare Cancer Care at Seven Hills
Henderson, Nevada, United States, 89052
21st Century Oncology-Henderson
Henderson, Nevada, United States, 89074
Comprehensive Cancer Centers of Nevada-Southeast Henderson
Henderson, Nevada, United States, 89074
Desert West Surgery
Las Vegas, Nevada, United States, 89102
OptumCare Cancer Care at Oakey
Las Vegas, Nevada, United States, 89102
University Medical Center of Southern Nevada
Las Vegas, Nevada, United States, 89102
Hope Cancer Care of Nevada
Las Vegas, Nevada, United States, 89103
Cancer and Blood Specialists-Shadow
Las Vegas, Nevada, United States, 89106
Radiation Oncology Centers of Nevada Central
Las Vegas, Nevada, United States, 89106
21st Century Oncology
Las Vegas, Nevada, United States, 89109
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
Las Vegas, Nevada, United States, 89109
HealthCare Partners Medical Group Oncology/Hematology-San Martin
Las Vegas, Nevada, United States, 89113
Radiation Oncology Centers of Nevada Southeast
Las Vegas, Nevada, United States, 89119
Cancer Therapy and Integrative Medicine
Las Vegas, Nevada, United States, 89121
21st Century Oncology-Vegas Tenaya
Las Vegas, Nevada, United States, 89128
Ann M Wierman MD LTD
Las Vegas, Nevada, United States, 89128
Cancer and Blood Specialists-Tenaya
Las Vegas, Nevada, United States, 89128
Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada, United States, 89128
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
Las Vegas, Nevada, United States, 89128
OptumCare Cancer Care at MountainView
Las Vegas, Nevada, United States, 89128
Comprehensive Cancer Centers of Nevada-Summerlin
Las Vegas, Nevada, United States, 89144
Summerlin Hospital Medical Center
Las Vegas, Nevada, United States, 89144
Las Vegas Cancer Center-Medical Center
Las Vegas, Nevada, United States, 89148-2405
21st Century Oncology-Fort Apache
Las Vegas, Nevada, United States, 89148
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States, 89148
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada, United States, 89148
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
Las Vegas, Nevada, United States, 89149
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, United States, 89169
University Cancer Center
Las Vegas, Nevada, United States, 89169
Hope Cancer Care of Nevada-Pahrump
Pahrump, Nevada, United States, 89048
Renown Regional Medical Center
Reno, Nevada, United States, 89502
Saint Mary's Regional Medical Center
Reno, Nevada, United States, 89503
Radiation Oncology Associates
Reno, Nevada, United States, 89509
United States, New Hampshire
New Hampshire Oncology Hematology PA-Concord
Concord, New Hampshire, United States, 03301
New Hampshire Oncology Hematology PA-Hooksett
Hooksett, New Hampshire, United States, 03106
United States, New Jersey
Virtua Memorial
Mount Holly, New Jersey, United States, 08060
Virtua Voorhees
Voorhees, New Jersey, United States, 08043
United States, New York
Montefiore Medical Center-Einstein Campus
Bronx, New York, United States, 10461
Montefiore Medical Center-Weiler Hospital
Bronx, New York, United States, 10461
Montefiore Medical Center - Moses Campus
Bronx, New York, United States, 10467
United States, North Carolina
Randolph Hospital
Asheboro, North Carolina, United States, 27203
Cone Health Cancer Center at Alamance Regional
Burlington, North Carolina, United States, 27215
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina, United States, 28328
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina, United States, 27534
Wayne Memorial Hospital
Goldsboro, North Carolina, United States, 27534
Cone Health Cancer Center
Greensboro, North Carolina, United States, 27403
Margaret R Pardee Memorial Hospital
Hendersonville, North Carolina, United States, 28791
Onslow Memorial Hospital
Jacksonville, North Carolina, United States, 28546
Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina, United States, 28546
Vidant Oncology-Kinston
Kinston, North Carolina, United States, 28501
Cone Heath Cancer Center at Mebane
Mebane, North Carolina, United States, 27302
Annie Penn Memorial Hospital
Reidsville, North Carolina, United States, 27320
United States, North Dakota
Sanford Bismarck Medical Center
Bismarck, North Dakota, United States, 58501
Sanford South University Medical Center
Fargo, North Dakota, United States, 58103
Sanford Broadway Medical Center
Fargo, North Dakota, United States, 58122
Sanford Roger Maris Cancer Center
Fargo, North Dakota, United States, 58122
Trinity Cancer Care Center
Minot, North Dakota, United States, 58701
United States, Ohio
Indu and Raj Soin Medical Center
Beavercreek, Ohio, United States, 45431
Strecker Cancer Center-Belpre
Belpre, Ohio, United States, 45714
Aultman Health Foundation
Canton, Ohio, United States, 44710
Dayton Physicians LLC-Miami Valley South
Centerville, Ohio, United States, 45459
Miami Valley Hospital South
Centerville, Ohio, United States, 45459
Geauga Hospital
Chardon, Ohio, United States, 44024
Adena Regional Medical Center
Chillicothe, Ohio, United States, 45601
University of Cincinnati/Barrett Cancer Center
Cincinnati, Ohio, United States, 45219
Good Samaritan Hospital - Cincinnati
Cincinnati, Ohio, United States, 45220
Oncology Hematology Care Inc-Kenwood
Cincinnati, Ohio, United States, 45236
Bethesda North Hospital
Cincinnati, Ohio, United States, 45242
TriHealth Cancer Institute-Westside
Cincinnati, Ohio, United States, 45247
TriHealth Cancer Institute-Anderson
Cincinnati, Ohio, United States, 45255
Case Western Reserve University
Cleveland, Ohio, United States, 44106
MetroHealth Medical Center
Cleveland, Ohio, United States, 44109
Mount Carmel East Hospital
Columbus, Ohio, United States, 43213
Columbus Oncology and Hematology Associates Inc
Columbus, Ohio, United States, 43214
Riverside Methodist Hospital
Columbus, Ohio, United States, 43214
Grant Medical Center
Columbus, Ohio, United States, 43215
The Mark H Zangmeister Center
Columbus, Ohio, United States, 43219
Mount Carmel Health Center West
Columbus, Ohio, United States, 43222
Doctors Hospital
Columbus, Ohio, United States, 43228
Good Samaritan Hospital - Dayton
Dayton, Ohio, United States, 45406
Miami Valley Hospital
Dayton, Ohio, United States, 45409
Dayton Physician LLC-Miami Valley Hospital North
Dayton, Ohio, United States, 45415
Miami Valley Hospital North
Dayton, Ohio, United States, 45415
Delaware Health Center-Grady Cancer Center
Delaware, Ohio, United States, 43015
Delaware Radiation Oncology
Delaware, Ohio, United States, 43015
Grady Memorial Hospital
Delaware, Ohio, United States, 43015
Mercy Cancer Center-Elyria
Elyria, Ohio, United States, 44035
Armes Family Cancer Center
Findlay, Ohio, United States, 45840
Blanchard Valley Hospital
Findlay, Ohio, United States, 45840
Orion Cancer Care
Findlay, Ohio, United States, 45840
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, United States, 45005-1066
Dayton Physicians LLC-Atrium
Franklin, Ohio, United States, 45005
Dayton Physicians LLC-Wayne
Greenville, Ohio, United States, 45331
Wayne Hospital
Greenville, Ohio, United States, 45331
Greater Dayton Cancer Center
Kettering, Ohio, United States, 45409
First Dayton Cancer Care
Kettering, Ohio, United States, 45420
Kettering Medical Center
Kettering, Ohio, United States, 45429
Fairfield Medical Center
Lancaster, Ohio, United States, 43130
OhioHealth Mansfield Hospital
Mansfield, Ohio, United States, 44903
Marietta Memorial Hospital
Marietta, Ohio, United States, 45750
OhioHealth Marion General Hospital
Marion, Ohio, United States, 43302
Toledo Clinic Cancer Centers-Maumee
Maumee, Ohio, United States, 43537
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
Maumee, Ohio, United States, 43537
UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor, Ohio, United States, 44060
UH Seidman Cancer Center at Southwest General Hospital
Middleburg Heights, Ohio, United States, 44130
Knox Community Hospital
Mount Vernon, Ohio, United States, 43050
Licking Memorial Hospital
Newark, Ohio, United States, 43055
Newark Radiation Oncology
Newark, Ohio, United States, 43055
University Hospitals Parma Medical Center
Parma, Ohio, United States, 44129
Mercy Health Perrysburg Cancer Center
Perrysburg, Ohio, United States, 43551
Southern Ohio Medical Center
Portsmouth, Ohio, United States, 45662
UH Seidman Cancer Center at Firelands Regional Medical Center
Sandusky, Ohio, United States, 44870
Springfield Regional Cancer Center
Springfield, Ohio, United States, 45504
Springfield Regional Medical Center
Springfield, Ohio, United States, 45505
Mercy Saint Anne Hospital
Toledo, Ohio, United States, 43623
Toledo Clinic Cancer Centers-Toledo
Toledo, Ohio, United States, 43623
Dayton Physicians LLC-Upper Valley
Troy, Ohio, United States, 45373
Upper Valley Medical Center
Troy, Ohio, United States, 45373
University Pointe
West Chester, Ohio, United States, 45069
Saint Ann's Hospital
Westerville, Ohio, United States, 43081
UH Seidman Cancer Center at Saint John Medical Center
Westlake, Ohio, United States, 44145
Genesis Healthcare System Cancer Care Center
Zanesville, Ohio, United States, 43701
United States, Oklahoma
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104
Integris Southwest Medical Center
Oklahoma City, Oklahoma, United States, 73109
Integris Cancer Institute of Oklahoma
Oklahoma City, Oklahoma, United States, 73142
Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa, Oklahoma, United States, 74146
United States, Oregon
Saint Alphonsus Medical Center-Baker City
Baker City, Oregon, United States, 97814
Saint Charles Health System
Bend, Oregon, United States, 97701
Clackamas Radiation Oncology Center
Clackamas, Oregon, United States, 97015
Providence Cancer Institute Clackamas Clinic
Clackamas, Oregon, United States, 97015
Bay Area Hospital
Coos Bay, Oregon, United States, 97420
Providence Newberg Medical Center
Newberg, Oregon, United States, 97132
Saint Alphonsus Medical Center-Ontario
Ontario, Oregon, United States, 97914
Providence Portland Medical Center
Portland, Oregon, United States, 97213
Providence Saint Vincent Medical Center
Portland, Oregon, United States, 97225
Saint Charles Health System-Redmond
Redmond, Oregon, United States, 97756
United States, Pennsylvania
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, United States, 18103
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, United States, 18017
Geisinger Medical Center
Danville, Pennsylvania, United States, 17822
Pocono Medical Center
East Stroudsburg, Pennsylvania, United States, 18301
Geisinger Medical Center-Cancer Center Hazleton
Hazleton, Pennsylvania, United States, 18201
Lehigh Valley Hospital-Hazleton
Hazleton, Pennsylvania, United States, 18201
Geisinger Medical Oncology-Lewisburg
Lewisburg, Pennsylvania, United States, 17837
Lewistown Hospital
Lewistown, Pennsylvania, United States, 17044
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140
Pottstown Hospital
Pottstown, Pennsylvania, United States, 19464
Geisinger Cancer Services-Pottsville
Pottsville, Pennsylvania, United States, 17901
Community Medical Center
Scranton, Pennsylvania, United States, 18510
Geisinger Medical Group
State College, Pennsylvania, United States, 16801
Reading Hospital
West Reading, Pennsylvania, United States, 19611
Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania, United States, 18711
United States, South Carolina
Prisma Health Cancer Institute - Laurens
Clinton, South Carolina, United States, 29325
Prisma Health Cancer Institute - Easley
Easley, South Carolina, United States, 29640
Prisma Health Cancer Institute - Butternut
Greenville, South Carolina, United States, 29605
Prisma Health Cancer Institute - Faris
Greenville, South Carolina, United States, 29605
Prisma Health Greenville Memorial Hospital
Greenville, South Carolina, United States, 29605
Prisma Health Cancer Institute - Eastside
Greenville, South Carolina, United States, 29615
Prisma Health Cancer Institute - Greer
Greer, South Carolina, United States, 29650
Prisma Health Cancer Institute - Seneca
Seneca, South Carolina, United States, 29672
Prisma Health Cancer Institute - Spartanburg
Spartanburg, South Carolina, United States, 29307
United States, South Dakota
Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota, United States, 57104
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, United States, 57117-5134
United States, Tennessee
Wellmont Bristol Regional Medical Center
Bristol, Tennessee, United States, 37620
Memorial Hospital
Chattanooga, Tennessee, United States, 37404
Pulmonary Medicine Center of Chattanooga-Hixson
Hixson, Tennessee, United States, 37343
Wellmont Medical Associates Oncology and Hematology-Johnson City
Johnson City, Tennessee, United States, 37604
Regional Cancer Center at Indian Path Community Hospital
Kingsport, Tennessee, United States, 37660
Wellmont Holston Valley Hospital and Medical Center
Kingsport, Tennessee, United States, 37660
Memorial GYN Plus
Ooltewah, Tennessee, United States, 37363
United States, Texas
Saint Joseph Regional Cancer Center
Bryan, Texas, United States, 77802
Parkland Memorial Hospital
Dallas, Texas, United States, 75235
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, United States, 75390
UT Southwestern/Simmons Cancer Center-Fort Worth
Fort Worth, Texas, United States, 76104
United States, Virginia
Wellmont Medical Associates-Bristol
Bristol, Virginia, United States, 24201
Southwest VA Regional Cancer Center
Norton, Virginia, United States, 24273
United States, Washington
Providence Regional Cancer System-Aberdeen
Aberdeen, Washington, United States, 98520
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, United States, 98225
Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington, United States, 98310
Harrison Medical Center
Bremerton, Washington, United States, 98310
Highline Medical Center-Main Campus
Burien, Washington, United States, 98166
Providence Regional Cancer System-Centralia
Centralia, Washington, United States, 98531
Swedish Cancer Institute-Edmonds
Edmonds, Washington, United States, 98026
Saint Elizabeth Hospital
Enumclaw, Washington, United States, 98022
Providence Regional Cancer Partnership
Everett, Washington, United States, 98201
Saint Francis Hospital
Federal Way, Washington, United States, 98003
Swedish Cancer Institute-Issaquah
Issaquah, Washington, United States, 98029
Kadlec Clinic Hematology and Oncology
Kennewick, Washington, United States, 99336
Providence Regional Cancer System-Lacey
Lacey, Washington, United States, 98503
Saint Clare Hospital
Lakewood, Washington, United States, 98499
PeaceHealth Saint John Medical Center
Longview, Washington, United States, 98632
Harrison HealthPartners Hematology and Oncology-Poulsbo
Poulsbo, Washington, United States, 98370
Pacific Gynecology Specialists
Seattle, Washington, United States, 98104
Swedish Medical Center-Ballard Campus
Seattle, Washington, United States, 98107
Kaiser Permanente Washington
Seattle, Washington, United States, 98112
Swedish Medical Center-First Hill
Seattle, Washington, United States, 98122-4307
Swedish Medical Center-Cherry Hill
Seattle, Washington, United States, 98122-5711
PeaceHealth United General Medical Center
Sedro-Woolley, Washington, United States, 98284
Providence Regional Cancer System-Shelton
Shelton, Washington, United States, 98584
Franciscan Research Center-Northwest Medical Plaza
Tacoma, Washington, United States, 98405
Northwest Medical Specialties PLLC
Tacoma, Washington, United States, 98405
PeaceHealth Southwest Medical Center
Vancouver, Washington, United States, 98664
Providence Saint Mary Regional Cancer Center
Walla Walla, Washington, United States, 99362
Providence Regional Cancer System-Yelm
Yelm, Washington, United States, 98597
United States, Wisconsin
Langlade Hospital and Cancer Center
Antigo, Wisconsin, United States, 54409
Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin, United States, 53105
Aurora Health Center-Fond du Lac
Fond Du Lac, Wisconsin, United States, 54937
Aurora Health Care Germantown Health Center
Germantown, Wisconsin, United States, 53022
Aurora Cancer Care-Grafton
Grafton, Wisconsin, United States, 53024
Aurora BayCare Medical Center
Green Bay, Wisconsin, United States, 54311
Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin, United States, 53142
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, United States, 54601
Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin, United States, 54143
Aurora Cancer Care-Milwaukee
Milwaukee, Wisconsin, United States, 53209
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, United States, 53215
Aurora Sinai Medical Center
Milwaukee, Wisconsin, United States, 53233
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, United States, 54017
Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin, United States, 54904
Aurora Cancer Care-Racine
Racine, Wisconsin, United States, 53406
Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan, Wisconsin, United States, 53081
Aurora Medical Center in Summit
Summit, Wisconsin, United States, 53066
Vince Lombardi Cancer Clinic-Two Rivers
Two Rivers, Wisconsin, United States, 54241
Aspirus Regional Cancer Center
Wausau, Wisconsin, United States, 54401
Aurora Cancer Care-Milwaukee West
Wauwatosa, Wisconsin, United States, 53226
Aurora West Allis Medical Center
West Allis, Wisconsin, United States, 53227
Aspirus UW Cancer Center
Wisconsin Rapids, Wisconsin, United States, 54494
United States, Wyoming
Billings Clinic-Cody
Cody, Wyoming, United States, 82414
Welch Cancer Center
Sheridan, Wyoming, United States, 82801
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Joel W Neal ECOG-ACRIN Cancer Research Group

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03468985    
Other Study ID Numbers: NCI-2017-01008
NCI-2017-01008 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
EA5152 ( Other Identifier: ECOG-ACRIN Cancer Research Group )
EA5152 ( Other Identifier: CTEP )
U10CA180820 ( U.S. NIH Grant/Contract )
First Posted: March 19, 2018    Key Record Dates
Last Update Posted: January 22, 2020
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Nivolumab
Ipilimumab
Antineoplastic Agents, Immunological
Antineoplastic Agents